Cannabis Science, Inc. (OTCBB:CBIS) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to voice our support for Gustin L. Reichbach, a justice of the State Supreme Court in Brooklyn NY. Cannabis Science is acknowledging his plea in The New York Times, where he supports medical marijuana and describes how it helped him with his Stage 3 Pancreatic Cancer.
Gustin L. Reichbach Op-Ed piece is a 'Judge's Plea for Pot' and he explains, "I was told I would be dead in four to six months, but I did not foresee that after having dedicated myself for 40 years to a life of the law, including more than two decades as a New York State judge, my quest for ameliorative and palliative care would lead me to marijuana." The judge continues to say his "survival has demanded an enormous price including months of chemotherapy, radiation hell and brutal surgery. For about a year, my cancer disappeared, only to return."
Furthermore he then states, "Nausea and pain are constant companions. One struggles to eat enough to stave off the dramatic weight loss that is part of this disease. Eating, one of the great pleasures of life has now become a daily battle, with each forkful a small victory. Every drug prescribed to treat one problem leads to one or two more drugs to offset its side effects. Pain medication leads to loss of appetite and constipation. Anti-nausea medication raises glucose levels, a serious problem for me with my pancreas so compromised. Sleep, which might bring respite from the miseries of the day, becomes increasingly elusive."
Reichbach continues, "Inhaled marijuana is the only medicine that gives me some relief from nausea, stimulates my appetite, and makes it easier to fall asleep. The oral synthetic substitute, Marinol, prescribed by my doctors, was useless. Rather than watch the agony of my suffering, friends have chosen, at some personal risk, to provide the substance. I find a few puffs of marijuana before dinner gives me ammunition in the battle to eat. A few more puffs at bedtime permits desperately needed sleep. This is not a law-and-order issue; it is a medical and a human rights issue."
Robert Melamede stated, "Every day we are touched by the individual faces of Medical Cannabis patients. From babies to centenarians, peoples are realizing the incredible effectiveness, safety, and broad applicability of cannabis-based medicines. Judge Gustin L. Reichbach is one of many patients confirming and sharing their medical cannabis success stories with the world. As politicians realize that their continuance is office is dependent on their recognition and support of medical marijuana, things will change. A recent demonstration that the times are changing, Rep Nancy Pelosi recently came out in against the anti-medical marijuana assaults, by federal policies and agents, on medical marijuana facilities. All of us at Cannabis Science thank and respect courageous heroes like Gustin L. Reichbach and all patients who share their stories. We encourage others to do likewise as the world wide movement to end cannabis prohibition grows with the volume of the patient's voice. Additionally we are proud that our Medical Advisory Board member, Dr. Alan Shackelford, has been meeting with legislators in New York and Connecticut to educate, them based on his knowledge and experiences, regarding the medical benefits of the cannabis plant."
The full editorial may be found here:
Gustin L. Reichbach's bio can be found here:
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
Robert Kane, 1-561-234-6929
VP Investor Relations